274 related articles for article (PubMed ID: 22734674)
1. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
Tripathy R; McHugh RJ; Ghose AK; Ott GR; Angeles TS; Albom MS; Huang Z; Aimone LD; Cheng M; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7261-4. PubMed ID: 22061645
[TBL] [Abstract][Full Text] [Related]
4. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
5. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
[TBL] [Abstract][Full Text] [Related]
6. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
[TBL] [Abstract][Full Text] [Related]
7. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
Mesaros EF; Thieu TV; Wells GJ; Zificsak CA; Wagner JC; Breslin HJ; Tripathy R; Diebold JL; McHugh RJ; Wohler AT; Quail MR; Wan W; Lu L; Huang Z; Albom MS; Angeles TS; Wells-Knecht KJ; Aimone LD; Cheng M; Ator MA; Ott GR; Dorsey BD
J Med Chem; 2012 Jan; 55(1):115-25. PubMed ID: 22141319
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
[TBL] [Abstract][Full Text] [Related]
11. Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core.
Han M; Wang C; Ji Y; Song Z; Xing L; Su Y; Wang X; Zhang A; Ai J; Geng M
Bioorg Med Chem Lett; 2016 Nov; 26(22):5399-5402. PubMed ID: 27769623
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.
Kinoshita K; Ono Y; Emura T; Asoh K; Furuichi N; Ito T; Kawada H; Tanaka S; Morikami K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
Bioorg Med Chem Lett; 2011 Jun; 21(12):3788-93. PubMed ID: 21561771
[TBL] [Abstract][Full Text] [Related]
13. 9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.
Kinoshita K; Kobayashi T; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Hattori K; Miyagi T; Hong WS; Park MJ; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
J Med Chem; 2011 Sep; 54(18):6286-94. PubMed ID: 21823617
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.
Michellys PY; Chen B; Jiang T; Jin Y; Lu W; Marsilje TH; Pei W; Uno T; Zhu X; Wu B; Nguyen TN; Bursulaya B; Lee C; Li N; Kim S; Tuntland T; Liu B; Sun F; Steffy A; Hood T
Bioorg Med Chem Lett; 2016 Feb; 26(3):1090-1096. PubMed ID: 26750252
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Jin C; Meng X; Sun D; Xu X; Zhou Y; Liang Z; Ji M; Li H; Xu T; Song G; Zhang L; Chen G; Yuan H; Shih J; Zhang R; Hou G; Jin Y; Yang Q
Bioorg Med Chem Lett; 2015 Sep; 25(17):3738-43. PubMed ID: 26130408
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).
Takeuchi CS; Kim BG; Blazey CM; Ma S; Johnson HW; Anand NK; Arcalas A; Baik TG; Buhr CA; Cannoy J; Epshteyn S; Joshi A; Lara K; Lee MS; Wang L; Leahy JW; Nuss JM; Aay N; Aoyama R; Foster P; Lee J; Lehoux I; Munagala N; Plonowski A; Rajan S; Woolfrey J; Yamaguchi K; Lamb P; Miller N
J Med Chem; 2013 Mar; 56(6):2218-34. PubMed ID: 23394126
[TBL] [Abstract][Full Text] [Related]
19. Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Gingrich DE; Lisko JG; Curry MA; Cheng M; Quail M; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Haltiwanger RC; Wells-Knecht K; Ott GR; Ghose AK; Ator MA; Ruggeri B; Dorsey BD
J Med Chem; 2012 May; 55(10):4580-93. PubMed ID: 22564207
[TBL] [Abstract][Full Text] [Related]
20. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
